Literature DB >> 8608131

Active site mutations define the pathway for the cooperative activation of cAMP-dependent protein kinase.

F W Herberg1, S S Taylor, W R Dostmann.   

Abstract

cAMP-dependent protein kinase (cAPK) is a heterotetramer containing two regulatory (R) and two catalytic (C) subunits. Each R-subunit contains two tandem cAMP-binding domains, and activation of cAPK is mediated by the cooperative, high affinity binding of cAMP to these two domains. Mutant R-subunits containing one intact high affinity cAMP-binding site and one defective site were used to define the pathway for activation and to delineate the unique roles that each cAMP-binding domain plays. Two mutations were introduced by replacing the essential Arg in each cAMP-binding site with Lys (R209K in Site A and R333K in Site B). Also, the double mutant (R209/333K) was constructed. Analysis of cAMP binding and dissociation and the apparent constants for holoenzyme activation and R- and C-subunit interaction, measured by analytical gel filtration and surface plasmon resonance, established the following: (1) For rR(R209K), occupancy of Site B is not sufficient to activate the holoenzyme; the low affinity Site A must also be occupied. In rR(R333K), Site A retains its high affinity for cAMP, but Site A cannot bind until the low affinity Site B is occupied. Thus, both mutants, for different reasons, have similar Ka's for activation that are approximately 20-fold higher than that of the wild-type holoenzyme. The double mutant with two defective sites is no worse than either single mutant. (2) Kinetic analysis of cAMP binding showed that the mutation in Site A or B abolishes high affinity cAMP binding to that site and slightly weakens the affinity of the adjacent site for cAMP. (3) In the presence of MgATP, both mutants rapidly form a stable holoenzyme even in the presence of cAMP in contrast to the wild-type R where holoenzyme forms slowly in vitro and requires dialysis. Regarding the mechanism of activation based on these and other mutants and from kinetic data, the following conclusions are reached: Site A provides the major contact site with the C-subunit; Site B is not essential for holoenzyme formation. Occupancy of Site A by cAMP mediates dissociation of the C-subunit. Site A is inaccessible to cAMP in the full length holoenzyme, while Site B is fully accessible. Access of cAMP to Site A is mediated by Site B. Thus Site B not only helps to shield Site A, it also provides the specific signal that "opens up" Site A. Finally, a nonfunctional Site A in the holoenzyme prevents stable binding of cAMP to Site B in the absence of subunit dissociation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8608131     DOI: 10.1021/bi951647c

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  51 in total

1.  Dynamic properties of regulatory motifs associated with induction of three temporal domains of memory in aplysia.

Authors:  David B Pettigrew; Paul Smolen; Douglas A Baxter; John H Byrne
Journal:  J Comput Neurosci       Date:  2005 Mar-Apr       Impact factor: 1.621

2.  Activation mechanisms for the cystic fibrosis transmembrane conductance regulator protein involve direct binding of cAMP.

Authors:  Malcolm M C Pereira; Jody Parker; Fiona L L Stratford; Margaret McPherson; Robert L Dormer
Journal:  Biochem J       Date:  2007-07-01       Impact factor: 3.857

3.  A simple electrostatic switch important in the activation of type I protein kinase A by cyclic AMP.

Authors:  Dominico Vigil; Jung-Hsin Lin; Christoph A Sotriffer; Juniper K Pennypacker; J Andrew McCammon; Susan S Taylor
Journal:  Protein Sci       Date:  2005-12-01       Impact factor: 6.725

Review 4.  Signaling through cAMP and cAMP-dependent protein kinase: diverse strategies for drug design.

Authors:  Susan S Taylor; Choel Kim; Cecilia Y Cheng; Simon H J Brown; Jian Wu; Natarajan Kannan
Journal:  Biochim Biophys Acta       Date:  2007-10-12

5.  High-affinity AKAP7delta-protein kinase A interaction yields novel protein kinase A-anchoring disruptor peptides.

Authors:  Christian Hundsrucker; Gerd Krause; Michael Beyermann; Anke Prinz; Bastian Zimmermann; Oliver Diekmann; Dorothea Lorenz; Eduard Stefan; Pavel Nedvetsky; Margitta Dathe; Frank Christian; Theresa McSorley; Eberhard Krause; George McConnachie; Friedrich W Herberg; John D Scott; Walter Rosenthal; Enno Klussmann
Journal:  Biochem J       Date:  2006-06-01       Impact factor: 3.857

6.  Two PKA RIα holoenzyme states define ATP as an isoform-specific orthosteric inhibitor that competes with the allosteric activator, cAMP.

Authors:  Tsan-Wen Lu; Jian Wu; Phillip C Aoto; Jui-Hung Weng; Lalima G Ahuja; Nicholas Sun; Cecilia Y Cheng; Ping Zhang; Susan S Taylor
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-30       Impact factor: 11.205

7.  A model of the roles of essential kinases in the induction and expression of late long-term potentiation.

Authors:  Paul Smolen; Douglas A Baxter; John H Byrne
Journal:  Biophys J       Date:  2006-01-13       Impact factor: 4.033

8.  Communication between tandem cAMP binding domains in the regulatory subunit of protein kinase A-Ialpha as revealed by domain-silencing mutations.

Authors:  E Tyler McNicholl; Rahul Das; Soumita SilDas; Susan S Taylor; Giuseppe Melacini
Journal:  J Biol Chem       Date:  2010-03-04       Impact factor: 5.157

9.  Neurochondrin is an atypical RIIα-specific A-kinase anchoring protein.

Authors:  Jennifer S Hermann; Philipp Skroblin; Daniela Bertinetti; Laura E Hanold; Eva K von der Heide; Eva-Maria Wagener; Hans-Michael Zenn; Enno Klussmann; Eileen J Kennedy; Friedrich W Herberg
Journal:  Biochim Biophys Acta       Date:  2015-04-23

10.  Dissecting interdomain communication within cAPK regulatory subunit type IIbeta using enhanced amide hydrogen/deuterium exchange mass spectrometry (DXMS).

Authors:  Kerri M Zawadzki; Yoshitomo Hamuro; Jack S Kim; Siv Garrod; David D Stranz; Susan S Taylor; Virgil L Woods
Journal:  Protein Sci       Date:  2003-09       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.